Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Acadia Pharmaceuticals (NASDAQ: ACAD) has announced the granting of inducement awards to twenty-two new employees under its 2024 Inducement Plan. The awards, approved by the Compensation Committee on April 3, 2025, include:

- Non-qualified stock options to purchase 172,637 shares at $16.12 per share
- 64,791 restricted stock units (RSUs)

The stock options will vest over 4 years, with 25% vesting after one year and the remainder monthly over 36 months. RSUs will vest over 4 years, with 50% vesting at the second anniversary and the remaining in two equal annual installments.

Acadia specializes in neuroscience breakthroughs and has developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Their clinical-stage pipeline includes programs for Prader-Willi syndrome and Alzheimer's disease psychosis.

Positive

• FDA-approved treatments in portfolio for both Parkinson's disease psychosis and Rett syndrome
• Diverse clinical pipeline targeting multiple neurological conditions
• Employee retention strategy through equity compensation

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 172,637 shares of common stock and 64,791 restricted stock units (“RSUs”) to twenty-two new employees under Acadia’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price per share equal to $16.12 per share, Acadia’s closing trading price on April 3, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with Acadia through the applicable vesting dates. The RSUs will vest over four years, with 50% of the underlying shares vesting on the second anniversary of the grant date, and the balance of the underlying shares vesting in two equal annual installments measured from the second anniversary of the grant date, subject to the new employees’ continued service relationship with Acadia through the applicable vesting dates. The awards are subject to the terms and conditions of Acadia’s 2024 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at Acadia.com and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250411125132/en/

Investor Contact:

Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.

Jessica Tieszen

(858) 261-2950

ir@acadia-pharm.com

Source: Acadia Pharmaceuticals Inc.

FAQ

What type of inducement awards did ACAD grant to new employees in April 2025?

ACAD granted non-qualified stock options for 172,637 shares at $16.12 per share and 64,791 RSUs to 22 new employees.

What is the vesting schedule for ACAD's 2025 stock option inducement grants?

The stock options vest over 4 years: 25% after one year, then monthly over 36 months.

How do the RSUs vest in ACAD's 2025 inducement grants?

RSUs vest over 4 years: 50% after two years, then two equal annual installments.

What therapeutic areas does ACAD focus on in their clinical pipeline?

ACAD focuses on Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuroscience and neuro-rare diseases.